Nucleoside triphosphates (NTPs) are vital components of emerging RNA therapeutics and vaccines. Controlling impurities that may be present in them while understanding key product quality attributes that make them suitable for good manufacturing practice (GMP) production is important for the successful development of these therapeutics and vaccines.
Download the following two white papers to help you recognize major impurities and identify quality attributes when looking for GMP-quality NTPs.
- Impurity profiling and analysis of TheraPure GMP* nucleotides
- Quality and consistency of N1-methylpseudouridine triphosphate
* "TheraPure GMP” refers to the quality level of the raw, ancillary, or starting materials to be used for further manufacturing. TheraPure GMP products are manufactured in facilities with ISO 9001–certified quality management systems that operate in accordance with relevant good manufacturing practice (GMP) principles, as outlined in ICH Q7 or equivalent guidance documents or standards.
